<DOC>
	<DOCNO>NCT02547961</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy HER2-CAR-T cell Infusion advance HER2 positive breast cancer .</brief_summary>
	<brief_title>Chimeric Antigen Receptor-Modified T Cells Breast Cancer</brief_title>
	<detailed_description>By enrol patient advance HER2 positive breast cancer adapt enrolled criterion , study document first time safety short long term efficacy HER2-CAR-T cell infusion advance HER2 positive breast cancer.The CAR consist HER-2 target antibody scFv two intracellular signal domain derive CD3 zeta CD28 . Autologous T cell gene-engineered CAR gene use retrovirus vector . Prior T cell infusion , patient subject precondition treatment . After T cell infusion , patient evaluate 24 month adverse reaction , persistence CAR T cell efficacy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Chemotherapy refractory Her2 positive breast cancer； 2 . Relapsed patient antiHer2 use antibody kinase inhibitor therapy； 3 . Patients must 18 year age older； 4 . Patients must ECOG ( Eastern Cooperative Oncology Group ) performance status 02； 5 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 . Platelet count great 100,000/mm3 . Hemoglobin great 10g/dl ( patient may receive transfusion meet parameter ) . Total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . Seronegative HIV antibody . Seronegative active hepatitis B , seronegative hepatitis C antibody . Patients must willing practice birth control four month follow treatment.NOTE : woman childbearing age must evidence negative pregnancy test . Patients must willing sign inform consent . 1 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure ( &gt; New York Heart Association Class II ) , myocardial infarction within 6 month study exclude . 2.Patients follo wing pulmonary function abnormality exclude : FEV ( forced expiratory volume ) , &lt; 30 % predict ; DLCO ( diffuse capacity lung carbon monoxide ) &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . 3.Patients severe liver kidney dysfunction consciousness disorder exclude . 4.Pregnant and/or lactate woman exclude . 5.Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 6.Patients type primary immunodeficiency exclude study . 7.Patients require corticosteroid ( inhale ) exclude . 8.Patients history T cell tumor exclude . 9.Patients participate participate clinical trial late 30 day exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>CAR-T cell</keyword>
</DOC>